BioNTech is expanding its horizon with significant
partnerships and
financial boosts. The pharmaceutical company recently paid $25M to reinforce their bond with
China's MediLink. Continuing their investment trends, BioNTech received a $145M funding from
CEPI aiming to ameliorate mRNA vaccine production capabilities in
Africa. This additional funding will further support vaccine development, with BioNTech gaining a platform license from a Chinese biotech for an antibody drug conjugate.
In the race of the COVID-19 vaccine patent,
Moderna has secured a victory over Pfizer-BioNTech in Europe. GSK, GlaxoSmithKline, has alleged Pfizer and BioNTech for infringing on their COVID-19 vaccine technology. Upon this news, BioNTech faced an underperforming market.
BioNTech has set its sights on
oncology, targeting commercial debut in 2026. Despite recently reporting a net loss, BioNTech remains optimistic about maintaining 90% of their 2024 revenues towards the end of the year. Furthermore, BioNTech's stock took a plunge after earnings missed the mark due to inventory write-downs.
BioNTech's shift to ADCs and CAR-Ts continues to drive its growth in 2024, and their focus on cancer treatment is anticipated to bring forth transformative advancements.
BIONTECH News Analytics from Mon, 07 Aug 2023 07:00:00 GMT to Fri, 31 May 2024 00:37:26 GMT -
Rating 3
- Innovation 8
- Information 7
- Rumor 1
